| 摘要 |
The present invention relates to equine amniotic membrane-derived mesenchymal stem cells (eAM-MSCs) and a method for producing same. More particularly, the present invention relates to equine amniotic membrane-derived mesenchymal stem cells showing negative immunological properties on human markers CD19, CD20, CD28, CD31, CD34, CD38, CD41a, CD62L, CD62P, and CD200, and also showing positive immunological properties on human markers CD44, CD90 and CD105. In addition, the present invention relates to equine amniotic membrane-derived mesenchymal stem cells that can be subcultured up to 14 or more times in an undifferentiated state and an ability to be differentiated into ectoblast, mesoblast and endoblast-derived cells. |
